$10.00 Million in Sales Expected for Interpace Diagnostics Group Inc (NASDAQ:IDXG) This Quarter

Equities research analysts expect Interpace Diagnostics Group Inc (NASDAQ:IDXG) to announce sales of $10.00 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Interpace Diagnostics Group’s earnings. The lowest sales estimate is $9.30 million and the highest is $10.70 million. Interpace Diagnostics Group posted sales of $5.75 million during the same quarter last year, which would indicate a positive year over year growth rate of 73.9%. The business is scheduled to report its next earnings report on Tuesday, November 12th.

According to Zacks, analysts expect that Interpace Diagnostics Group will report full year sales of $33.92 million for the current financial year, with estimates ranging from $33.30 million to $34.53 million. For the next fiscal year, analysts forecast that the firm will report sales of $51.38 million, with estimates ranging from $49.65 million to $53.10 million. Zacks’ sales averages are an average based on a survey of research firms that cover Interpace Diagnostics Group.

Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Tuesday, August 13th. The business services provider reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). The firm had revenue of $6.27 million for the quarter, compared to analyst estimates of $6.70 million. Interpace Diagnostics Group had a negative return on equity of 42.91% and a negative net margin of 65.86%.

A number of equities research analysts recently issued reports on the stock. Oppenheimer assumed coverage on shares of Interpace Diagnostics Group in a research report on Thursday, September 26th. They set an “outperform” rating and a $3.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of Interpace Diagnostics Group in a research report on Tuesday, October 1st. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Interpace Diagnostics Group presently has a consensus rating of “Buy” and an average target price of $3.00.

Shares of Interpace Diagnostics Group stock traded down $0.02 during mid-day trading on Friday, reaching $0.79. 66,468 shares of the stock were exchanged, compared to its average volume of 135,528. The company has a market cap of $30.75 million, a price-to-earnings ratio of -1.84 and a beta of 2.29. The company has a current ratio of 1.75, a quick ratio of 1.75 and a debt-to-equity ratio of 0.06. The firm has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $0.76. Interpace Diagnostics Group has a fifty-two week low of $0.67 and a fifty-two week high of $1.55.

A number of institutional investors and hedge funds have recently bought and sold shares of IDXG. Stonepine Capital Management LLC increased its position in Interpace Diagnostics Group by 22.3% in the 2nd quarter. Stonepine Capital Management LLC now owns 1,753,184 shares of the business services provider’s stock valued at $1,271,000 after acquiring an additional 319,154 shares in the last quarter. River & Mercantile Asset Management LLP acquired a new stake in Interpace Diagnostics Group in the 2nd quarter valued at about $468,000. Finally, Cambridge Investment Research Advisors Inc. increased its position in Interpace Diagnostics Group by 98.0% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 44,750 shares of the business services provider’s stock valued at $32,000 after acquiring an additional 22,150 shares in the last quarter. Hedge funds and other institutional investors own 20.68% of the company’s stock.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Recommended Story: Inverted Yield Curve

Get a free copy of the Zacks research report on Interpace Diagnostics Group (IDXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Interpace Diagnostics Group (NASDAQ:IDXG)

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.